Bilastine: In allergic rhinitis and Urticaria

Drugs

Volumn 72, Issue 9, 2012, Pages 1257-1269

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Allergic rhinitis; Bilastine; Urticaria

Indexed keywords

ALLERGEN; BILASTINE; CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE; HYDROXYZINE; KETOCONAZOLE; LEVOCETIRIZINE; ORGANIC CATION TRANSPORTER 1; PLACEBO;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CHRONIC URTICARIA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GLOMERULUS FILTRATION RATE; GRASS POLLEN; HUMAN; NONHUMAN; PERENNIAL RHINITIS; PLASMA CLEARANCE; SOMNOLENCE; SYMPTOM; TREATMENT RESPONSE;

AREA UNDER CURVE; BENZIMIDAZOLES; CETIRIZINE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; URTICARIA;

EID: 84862151153     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209310-000000000-00000     Document Type: Article

References (33)

1. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl. 1): s147-334
2. Pawankar R, Canonica GW, Holgate ST, et al. World Allergy Organization white book on allergy 2011-2012: executive summary [online]. Available from URL: http://www.worldallergy.org/publications/wao-white-book.pdf [Accessed 2012 Mar 14]
3. Wedi B. Urticaria. J Dtsch Dermatol Ges 2008 Apr; 6 (4): 306-17
4. Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128 (6): 1139-50
5. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64 (10): 1427-43
6. Golan DE, Tashjian AH Jr, Armstrong EJ, et al. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Versailles (KY): Lippincott Williams & Wilkins, 2008
7. Broek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-76
8. Obradovic T, Dobson GG, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 2007 Feb; 24 (2): 318-27 (Pubitemid 46072191)
9. Chen C, Hanson E, Watson JW, et al. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003 Mar; 31 (3): 312-8 (Pubitemid 36249686)
10. Lieberman P. Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc 2009; 30 (5): 482-6
11. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10 (5): 779-93
12. A. Menarini Pharma UK. Ilaxten (bilastine) 20 mg tablets: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/EMC/medicine/24461/SPC/Ilaxten+20+mg+tablets/[Accessed 2012 Mar 23]
13. Faes Farma. Bilastine (Bilaxten): Spanish summary of product characteristics [online]. Available from URL: http://www.bilastina.com/ Downloads/Documents/SMPCEN. pdf [Accessed 2012 Mar 27]
14. Faes Farma. Bilastine (Bilaxten): product monograph [online]. Available from URL: http://www.bilastina.com/Book. aspx?lang=en&name= Monograph&File=Downloads/Doc uments/monografiaEN.pdf&DPI=300 [Accessed 2012 Mar 27]
15. Corcó stegui R, Labeaga L, Innerá rity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Drugs R D 2005; 6 (6): 371-84
16. Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006; 7 (4): 219-31 (Pubitemid 43927202)
17. Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res 2011; 60 (12): 1107-12
18. Garća-Gea C, Martinez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008 Dec; 28 (6): 675-85
19. Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic- pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009; 48 (8): 543-54
20. Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39 (9): 1338-47
21. Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20mg vs desloratadine 5mg in seasonal allergic rhinitis patients. Allergy 2009; 64 (1): 158-65
22. Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5mg for the treatment of chronic idiopathic urticaria: a multicentre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65 (4): 516-28
23. Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010; 65 Suppl. 93: 1-13
24. Conen S, Theunissen EL, Van Oers ACM, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011 Nov; 25 (11): 1517-23
25. Garća-Gea C, Clos S, Antonijoan RM, et al. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects [abstract no. EC13]. Basic Clin Pharmacol Toxicol 2006; 99 Suppl. 1: 30
26. Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol. Epub 2011 Jun 3
27. Graff C, Struijk JJ, Kanters JK, et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig 2012; 32 (5): 339-51
28. Crean CS, Roupe KR, Sologuren A, et al. The pharmacokinetics of bilastine after single and 14 days once daily administration [abstract no. P252]. Basic Clin Pharmacol Toxicol 2007; 101 Suppl. 1: 148
29. Gonzalo A, Lucero ML, Orjales A, et al. Identification of processes involved in bilastine bioavailability in rats [abstract no. 69]. 10th European ISSX Meeting; 2008 May 18-21; Vienna
30. Sologuren A, Lucero ML, Valiente R, et al. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers [abstract no. TP85]. Basic Clin Pharmacol Toxicol 2009; 105 Suppl. 1: 106-7
31. Sastre J, Mullol J, Valero A, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28 (1): 121-30
32. Horak F, Zieglmayer P, Zieglmayer R, et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59 (5): 391-8
33. Montoro J, del Cuvillo A, Já uregui I, et al. Bilastine and the central nervous system: incidence of somnolence [abstract no. 926]. Allergy 2011; 66 Suppl. 94: 358